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Abstract
Cardiovascular diseases (CVDs) are ones of the major death-causing
issues in Kazakhstan which are needed to be solved. Different pro-
grams have been implemented in order to reduce the incidence of
CVDs and the screening program is the one of them. The aim of
this research is to identify the effectiveness of the screening program
through assessing the hospitalization of the patients. After adjust-
ing inclusion and exclusion criteria, the data obtained from polyclinic
#5 of Astana contained medical records of 12 191 people in the age
group of 41-59. Logit regression model analysis was used to find the
significance of the independent variables and its effects. Addition-
ally, average marginal effects were considered to represent the change
in probability of outcomes. The results show that influence of the
screening participation is not high enough to conclude that hospital-
ization depends on it. On the other hand, patients that participated
twice in the program had lower chances of being hospitalized.
Keywords: screening program, cardiovascular disease, screening ef-
fectiveness
Introduction
Since the introduction of the first screening program, it has shown out-
standing results in terms of early detection of diseases (Morabia & Zhang,
2004). Many lives were saved, which is crucial from ethical point of view.
However, the effectiveness of the program is still debated by economists.
Stout et al. (2006) suggest that the screening campaigns are too costly to
implement. While Hackl et al. (2015) say that the screening programs bring
even higher costs to the patients themselves in future. The defenders of the
program talk about future savings that can be even greater than costs(Kones,
2011).
According to International Agency for Research on Cancer (WHO, 2005),
four methods have been used to assess the effectiveness of screening:
(i) individual-based studies using case-control or cohort designs; (ii) corre-
lating screening activity with changes in mortality or incidence rates across
time, place or age group; (iii) modelling of screening policy and practice to
estimate effectiveness; (iv) evaluation of operational parameters of screening.
The latter includes screening performance indicators such as participation,
quality and adequacy of follow-up of positive test results.
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This research paper investigates the effectiveness of screening program
on early detection and prevention of cardiovascular diseases corresponding
to the 2nd method provided above through the prism of labor supply.
I expect that the screening program is effective in sustaining high level
of labor supply. In Kazakhstan, every patient with cardiovascular disease
is registered and given recommendations about their diet and physical ac-
tivity. Since CVDs are the most common illnesses in the country (WHO,
2015), to combat the problem government guarantees full medical care for
the patients. Consequently, citizens of Kazakhstan are given medicine drugs
against various diseases (CVDs included) on a free basis (Ministry of Justice,
2009).
This investigation can bring a significant contribution to the development
of the screening programs, as the research is done using unique data set. Even
if the paper does not touch the topic of costs and benefits, it will mainly be
focused on human behavior. The data allows me to identify the importance
of health screening to the people and, as a result, constitute whether the use
of screening programs is effective for labor supply attachment.
Literature Review
One of the researches related to my study is conducted by Hackl et al.
(2015). In the research, they use data on Austrian mass screening program
that was launched in 1974. The authors study the effect of screening program
on health expenditures and health status. They state that participation
in screening program increases the expenditures on healthcare for the next
several years. Thus, they conclude that the implementation of screening
programs is not favorable to recommend.
While the previous research is conducted on many types of diseases, some
other teams, such as Cole et al. (2002) and Hardcastle et al. (1996), focus
only on screening of colorectal cancer. After analyzing the data, they identify
that the cancer is rarely found among people participating in the screening
program.
In fact, Rosendaal et al. (2016) clearly states that CVD is the lead-
ing reason of the mortality worldwide, especially in low- and middle-income
countries. Furthermore, it is concluded that CVDs alter the productivity of
the workers. The authors suggest that primary and secondary medical care
including screenings as well as antihypertensive treatments provided by dif-
ferent health care organizations may help to identify and reduce the illness
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at the early stages. By doing the analysis, they find out that the screening
programs are effective tool to identify the disease in Nigeria, though, only
when it is provided to patients on the free basis.
Screening programs are the effective tools to identify CVDs to reduce
the mortality caused by these diseases. It is found out that approximately
10% of men diagnosed with CVDs are associated with 25-30% of overall
mortality rate (Grndal et al., 2015). Moreover, 50% of these men have the
arterial hypertension. The authors suggest that the early detection of health
problems related to CVDs will help to organize prophylactic actions such as
drug therapies and the control of blood pressure. The study is evaluating
the attendance and detection rates of screening programs for CVDs. As a
result of the study, it is concluded that the distance to the screening location
influences significantly on the attendance and decision to participate.
Zou et al. (2007) conduct the study that evaluates diagnostic tests via
a non-parametric method of analysis, known as Receiver-operating model.
The authors highlight the main issues that may arise while evaluating the
effectiveness of the diagnostic programs. They include verification bias and
measurement error. Verification bias may occur when those patients who
were already known to have the disease are included into the analysis. Mea-
surement error may occur, when patients that are imperfectly matched the
desired characteristics are included into the analysis (Zou et al., 2007).
In my work, I do not have data on individual expenditures. The reason is
that I suppose people not spending money on healthcare, because government
is already supplying medicine and drugs on a free basis (medicine is given
with prescription only). I focus my attention on CVDs, which are known to
be ones of the most widespread diseases in Kazakhstan leading to more than
50% of deaths per year (WHO, 2014). As the health care in Kazakhstan is
provided on the free basis, I suppose that the effect of the screening programs
would be negative (decrease probability of labor supply loss) in Kazakhstan.
In this study I will include the patients that are registered in particular
polyclinics near their houses. Moreover, polyclinics are widely using mobile
laboratories to access the patients on their workplaces. Therefore, I expect
that the attendance of patients will be high and I will be able to receive more
accurate results without many missing data. I will try to escape the errors
shown above by excluding those patients that already have CVDs prior the
screening process as well as including to the analysis only those patients that
highly match the desired characteristics. The perfect match is a patient of
ages 41-59, not registered as CVD positive.
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Background information
A well-developed healthcare system is essential to improve the quality
of life in country. During the Soviet time, healthcare in Kazakhstan was
based on Semashko model that was focused on provision of high numbers of
hospital beds and doctors, instead of provision of good facilities and achieving
positive outcomes. Therefore, there was centralized planning of the medical
care (MacLehose, 2002). For instance, every citizen was provided with same
free medical care. However, the main emphasis of this model was not on
prevention, but on tertiary health care. According to WHO, in order to
establish good health system, well-maintained facilities and policies should
be organized (Health systems, n.d.).
After the collapse of Soviet Union, when Kazakhstan had faced the issues
with the system of healthcare, new health system was aimed to be investi-
gated. This time, the model targeted on prevention rather than on treatment
was used as a base. Kazakhstan-2030 program was established in 1997 and
one of the targets was to improve quality and productivity of labor force
via investing in health care (Utegenova, 2015). After 1997, the program was
modified and thus the healthcare in Kazakhstan moved to the next stage of
development.
Programs such as Salamatty Kazakhstan or Densaulyk 2016-2019 were
introduced. One of such programs is a screening program which was pre-
sented in 2008. The main goal of it was to identify the most life-threatening
diseases at early stages and lower their effects on human health. The pro-
gram targeted the most widespread diseases such as arterial hypertension,
breast cancer and cervical cancer. In 2011, the program was expanded to
cover some other diseases such as glaucoma, stomach cancer, diabetes and
etc.
As cardiovascular diseases (CVDs) cause more than half of the fatalities
in Kazakhstan (Townsend et. al, 2016), it is crucial to identify the disease
at the early stages. One of the most common CVDs is arterial hypertension.
According to Shinbolatova et. al (2014), the prevalence of this disease
4
Figure 1. New cases of of diseases of the circulatory system per 100 000
population Source: Data Presentation System Kazakhstan
was 24.1%. The number of explored cases associated with circulatory system
steadily increases every year (Figure 1). Moreover, the mortality rate associ-
ated with CVDs has increased as shown in Figure 2. Approximately 40% of
the deaths are found out to occur during active working age. Therefore, the
screening age for cardiovascular diseases was set to between 34 and 64 years.
However, as the level of detection was low, the range was later shortened to
40-64 years in 2009 (Ministry of Justice). Also the 64% of all deaths due to
CVDs are among male population.
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Figure 2. Deaths by cause in Kazakhstan. Source: World Health Organization
To deal with these issues, the State Health System of Kazakhstan came
out with the screening program that aimed on early detection of CVDs and
its risk factors. These screening programs were established in 2008 and the
patients had an opportunity to take the screening tests on a free basis as
well as get free treatment therapies. However, even after establishment of
these programs the epidemiology did not change significantly. The possible
reasons of that were the lack of response by population or not taking the
disease seriously by population (Shinbolatova et al., 2014).
Data
In Kazakhstan, any citizen has a freedom to choose primary healthcare
organization that will be providing healthcare services. However, after being
registered in one of the organizations, other organizations do not provide any
services, except emergency cases. In order to get the treatment, the patient
needs to sign out of the previous medical organization and register again in
the new one (Ministry of Justice, 2015). Consequently, the primary health-
care organizations have the lists of screening participants that are registered
to them. In Astana, there are 12 polyclinics and 7 health centers that are
responsible for primary healthcare. In this study, I used the data from Poly-
clinic 5 only as the rest of the data is restricted. The panel data contains
medical records of 68 596 people on gender, age, screening participation and
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Table 1: Summary statistics of the data set
Variable Year Treated Not treated Total mean
Hospitalization
2012 .0229787 .0289362
.0281355
2013 .0392927 .0255403
2014 .0241449 .028169
2015 .0363973 .0277606
Age
2012 49.20851 48.78894
49.0228
2013 50.06876 48.65324
2014 48.57867 49.17062
2015 50.00802 48.7261
Male
2012 .4034043 .452766
.4444262
2013 .4238703 .456778
2014 .4676056 .4430584
2015 .4324491 .4441703
CVD morbidity. The data for gender, age and screening participation were
easily available, while the data on visits to the doctors and emergency calls
related to the CVD morbidity were digitized manually. Moreover, because
the attached population is changing almost every day (due to migration), I
use only the participants who have been attached to the polyclinic 5 for the
whole time period in my research.
As I am interested only in the effectiveness of the screening program which
has spillover effects on labor supply, I focus on the age group 41-59. I omit
those people that already had cardiovascular diseases before the time scale
of my research. As a result, after analyzing inclusion and exclusion criteria,
the records on 12 191 people were selected, of whom: 5 418 men and 6 773
women; 343 of them were served by medical organization in 2015-2016 with
CVD diagnoses and 11 848 did not.
One important note to make is that if a patient visits medical organization
without being on the list, he is not counted as screened. This point again
prooves the randomness of the data.
One of the main variables that could have great importance in the model
is income level. I expect that people with higher income are less exposed
to CVDs due to better diet and lower level of stress. On the other hand,
since all the medical needs are supplied for free, it is possible that income
level would play a major role in hospitalization occurrence. However, due to
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unavailability of this information in open access data, I omit it in my model.
The research might have information biases that could bring measure-
ment errors. For example, it might be that medical personnel could make
a mistake while registering the patients in the digital database. Another
reason could lie in handwritten journals. Sometimes it happens that a name
was misspelled or the diagnosis was written incorrectly. In addition, the data
error could be in the screening results.
Model
To analyze the effect of screening program I use logit regression model.
The logit model is used in statistics when the regression is run on the depen-
dent variable that has only 2 values. Specifically, the logit regression shows
the probability that an observation with particular set of characteristics will
have one of the values (Freedman, 2009).
Since I do not have data for labor supply, I use the data on hospital-
ization as a proxy for it. I assume that labor supply decreases every time
the patient is visiting the hospital. Therefore, my dependent variable is the
hospitalization data. The data account for the visits in hospital that lasted
more than 3 days (up to one month). The hospitalization data is shown as a
binary variable, where 1 means that the patient visited the hospital or called
emergency services within a year and 0 otherwise.
The independent variables in my research are age, gender and screening
participation. Both gender and screening participation data are dummy vari-
ables that equal to 1 if the patient is male and participated in the screening
program, respectively. The age data vary between 41 and 59 years. Since the
data on screening differ for every year, I use dummies to differentiate them.
A simple linear regression model would be:
pr[hosp = 1|x] = xβ,
where: - the dependent variable, indicating whether the patient was hospital-
ized within a surveyed year or not; - the set of independent variables: age of
the patients and dummies for gender and screening participation. However,
this model does not restrict probabilities between values 0 and 1. Conse-
quently, the results of the regression are not considered as reliable.
The logit regression model is as follows:
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pr[hosp = 1|x] = F (xβ) = e
xβ
1− exβ ,
where F (xβ) is the CDF of logistic distribution. Using this model, we
can find the significance of the independent variables and their effects (posi-
tive/negative). However, to find their magnitudes I use the average marginal
effects, which represent the change in probability of outcome being equal to
1 when an independent variable is changed by one unit.
Results
The overall results can be seen from the Table 2 below. The column (1)
shows the overall logit regression. The last 4 regressions show separate logit
regression for ages 41-45 (2), 46-50 (3), 51-55 (4), 56-59 (5).
The regression analysis shows negative and non-significant effect of screen-
ing participation on hospitalization outcome. Overall, the age variable shows
high significance to the hospitalization. The sign of the coefficients assumes
that as people get older, the probability of hospitalization increases. The
variable depicting the gender of the patients, male, showed high significance
only in the older ages. It assumes that men have higher chances of get-
ting hospitalized than women. Overall, however, the gender variable is not
significant.
Table 3 shows the average marginal effects in each case. The following
coefficients show how 1 unit increase of a variable affect the probability of
hospitalization.
The most significant result was found in the importance of age. It was
found out that age variable is positively related to hospitalization.
In case of gender differences, the probability of males getting hospitalized
is higher by 4.43% between ages 56-59, meaning significant difference with
females. In other regressions, the coefficient for gender is not enough to make
sense.
Among variables representing screening programs, scrn2013 showed pos-
itive relationship with hospitalization. This means that patients that par-
ticipated in screening program in the year 2013 had more chances of getting
hospitalized. This is particularly true for the patients aged 51-55. On the
other hand, the scrn2014 in the regression of ages 39-45, vice versa, has
negative relationship with hospitalization.
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Overall, the main variables in my research showed in most of the regres-
sions negative sign. However, due to high variation around zero I assume
that the effect is not meaningful.
In addition, I also checked whether participation in screening 2 times
plays role in this model. Here, var1214 show that the patient participated
in screening in 2012 but did not in 2014; var1412 show that the patient
participated in screening in 2014 but did not in 2012; and var12141 shows
that the patient participated in both screenings. The same is with var1315,
var1513 and var13151. However, in this amalysis I omit var1513 due to
perfect failure, which means that it is not playing any role in the analysis.
This model shows the same results for the age and gender variables. One
of the findings of this model is that the coefficients for var1214 and var1315
are greater than for var12141 and var13151 respectively. This means that
patients passing the screening twice have lower chances of hospitalization
occurrence.
For better interpretation of the results I use average marginal effects in
Table 5. There you can see the magnitudes of the relationship between the
dependent and independent variables. A patient passing the screening in
both 2012 and 2014 have approximately 1.5% lower probability of hospital-
ization than a patient passing screening only in 2012. In addition, he/she has
1.3% lower chances than 2015 screening participant. A patient passing the
screening in both 2013 and 2015 have approximately 0.8% lower probability
of hospitalization than a patient passing screening only in 2013.
Table 2. Logit regression model
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Ages 41-59 Ages 41-45 Ages 46-50 Ages 51-55 Ages 56-59
hosp hosp hosp hosp hosp
hosp
male 0.192 -0.517 0.174 -0.0227 0.952∗∗∗
(1.74) (-1.70) (0.72) (-0.13) (4.14)
age 0.637∗∗
(2.76)
age2 -0.00535∗
(-2.35)
scrn2012 -0.173 0.260 -0.427 -0.0826 -0.0787
(-0.81) (0.41) (-1.03) (-0.22) (-0.20)
scrn2013 0.496∗ 0.293 0.320 0.740∗ 0.00778
(2.14) (0.44) (0.47) (2.42) (0.01)
scrn2014 -0.00794 -1.090∗ 0.243 0.104 0.0448
(-0.05) (-1.98) (0.88) (0.38) (0.16)
scrn2015 -0.277 0.0221 -0.241 -0.386 -0.0347
(-1.09) (0.03) (-0.32) (-1.16) (-0.06)
cons -22.05∗∗∗ -4.057∗∗∗ -3.956∗∗∗ -3.249∗∗∗ -3.474∗∗∗
(-3.79) (-20.60) (-19.80) (-22.14) (-16.91)
N 12191 3894 3376 3124 1797
t statistics in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table 3. Average Marginal Effects
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Ages 41-59 Ages 41-45 Ages 46-50 Ages 51-55 Ages 56-59
hosp hosp hosp hosp hosp
hosp
male 0.05 -0.0067 0.0036 -0.0009 0.0443∗∗∗
(1.74) (-1.66) (0.72) (-0.13) (3.91)
age 0.017∗∗
(2.73)
age2 -0.000145∗
(-2.34)
scrn2012 -0.005 0.0034 -0.0088 -0.0033 -0.0037
(-0.81) (0.41) (-1.02) (-0.22) (-0.20)
scrn2013 0.013∗ 0.0038 0.0066 0.0299∗ 0.00036
(2.13) (0.44) (0.47) (2.38) (0.01)
scrn2014 -0.00022 -0.014∗ 0.005 0.042 0.0021
(-0.05) (-1.91) (0.87) (0.38) (0.16)
scrn2015 -0.007 0.00029 -0.005 -0.0156 -0.0016
(-1.09) (0.03) (-0.32) (-1.15) (-0.06)
N 12191 3894 3376 3124 1797
t statistics in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table 4. Logit regression model with several cases
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Ages 41-59 Ages 41-45 Ages 46-50 Ages 51-55 Ages 56-59
hosp hosp hosp hosp hosp
hosp
male 0.191 -0.510 0.173 -0.0283 0.946∗∗∗
(1.73) (-1.68) (0.72) (-0.16) (4.11)
age 0.633∗∗
(2.74)
age2 -0.00531∗
(-2.33)
var1214 0.0871 0.364 -0.713 0.409 0.249
(0.32) (0.49) (-0.98) (0.93) (0.51)
var1412 0.0761 -1.022 0.189 0.287 0.163
(0.47) (-1.69) (0.63) (1.00) (0.53)
var12141 -0.403 -0.991 -0.0683 -0.497 -0.370
(-1.34) (-0.97) (-0.14) (-0.83) (-0.61)
var1315 0.517∗ 0.607 0.218 0.747∗ -0.0543
(2.18) (0.99) (0.30) (2.37) (-0.09)
var13151 0.234 0.225 0.0934 0.399 0.0215
(1.54) (0.57) (0.23) (1.78) (0.07)
cons -21.95∗∗∗ -4.065∗∗∗ -3.940∗∗∗ -3.282∗∗∗ -3.497∗∗∗
(-3.77) (-20.43) (-19.59) (-21.95) (-16.83)
N 12191 3894 3376 3124 1797
t statistics in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table 5. Average Marginal Effects
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Ages 41-59 Ages 41-45 Ages 46-50 Ages 51-55 Ages 56-59
hosp hosp hosp hosp hosp
hosp
male 0.0052 -0.0066 0.0036 -0.0011 0.0441∗∗∗
(1.73) (-1.64) (0.72) (-0.16) (3.89)
age 0.0172∗∗
(2.71)
age2 -0.0001∗
(-2.32)
var1214 0.0024 0.00469 -0.0147 0.0165 0.0116
(0.32) (0.49) (-0.97) (0.93) (0.51)
var1412 0.0021 -0.013 0.0039 0.0116 0.0076
(0.47) (-1.65) (0.63) (1.00) (0.53)
var12141 -0.0109 -0.0128 -0.0014 -0.0201 -0.0172
(-1.33) (-0.97) (-0.14) (-0.83) (-0.61)
var1315 0.014∗ 0.0078 0.0045 0.03∗ -0.0025
(2.17) (0.99) (0.30) (2.34) (-0.09)
var13151 0.0063 0.0029 0.0019 0.0161 0.001
(1.53) (0.57) (0.23) (1.77) (0.07)
N 12191 3894 3365 3111 1791
t statistics in parentheses
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Discussion
In this study, I expected that the screening program with its so many
advantages will have significant effect in decreasing hospitalization outcome.
In addition, I assumed that as people get older the chances of unexpected
health issues increase, too. In case of gender, the national statistics on mor-
tality rates have made me to believe that males are much less aware of own
health. Consequently, they are getting to hospital more often.
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The results, however, did not meet my expectations fully. It was found
that screening program participation did not play significant role in decreas-
ing hospitalization frequency among the observed population. I suppose that
patients participating in the screening program failed to control own diet or
use opportunities provided by government on a free basis such as medicine
and healthcare services. The incidence of hospitalization among both groups
was almost the same. The age variable showed high significance for hos-
pitalization. It was found that as people get older, the chances of being
hospitalized increase, even though the rate of increase is declining. The gen-
der variable, on its turn, was not significant factor up to the age group of
56-59. In this case, males have higher chances of hospitalization than women.
The outcomes of the analysis have several implications. Firstly, insignif-
icance of the variable representing screening participation can be used in
reevaluation of the government funding in the program. One of the rec-
ommendations I can make is to decrease the funding of medicine drugs to
registered patients. In addition, I suggest medical organizations to increase
awareness of the male population regarding self-care.
One of the limitations of this study is that I do not have data on the
severeness of the diseases that are found among the population. One could
find out about own CVD on the latest stages, when only stationary healthcare
is effective. However, since the program was launched in 2008 and it screens
up to 50% of population of selected ages, the chances of revealing patients
with severe CVD is very low. On the other hand, the medical personnel do
not have rights to force people to pass screening.
Another limitation is that my study was made only on cardiovascular
diseases, which is only one out of 9 screening procedures that are made in
the program. Consequently, the results do not fully show the effectiveness of
the program that is highly respected internationally.
Regarding future studies, I suggest to add more variables, for instance the
severeness of the disease or data on other screening procedures. In addition,
this study can be implemented in all hospitals to assess the effectiveness of
the screening program on whole Astana population.
Conclusion
This paper investigated the effectiveness of the screening program on la-
bor supply on example of cardiovascular diseases in one of the city policlinics.
Study was conducted among men and women aged 41-59. The data was an-
alyzed using logit regression. It was revealed that the effectiveness of the
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screening program is low, meaning that the participation does not influence
on probability of hospitalization. On the other hand, the analysis showed that
repeated screening lowers the chances of hospitalization. Moreover, possible
sources of error and limitations were identified as well as future directions
were suggested.
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